Stonepine Capital Management LLC acquired a new stake in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 18,600 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Intercept Pharmaceuticals accounts for 0.6% of Stonepine Capital Management LLC’s portfolio, making the stock its 18th largest holding. Stonepine Capital Management LLC owned 0.07% of Intercept Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ICPT. Balyasny Asset Management LLC bought a new stake in Intercept Pharmaceuticals in the 2nd quarter valued at about $13,766,000. Vanguard Group Inc. raised its stake in Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after acquiring an additional 57,149 shares during the period. First Trust Advisors LP raised its stake in Intercept Pharmaceuticals by 17.0% in the 2nd quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock valued at $34,797,000 after acquiring an additional 41,856 shares during the period. Quantitative Investment Management LLC bought a new stake in Intercept Pharmaceuticals in the 2nd quarter valued at about $3,728,000. Finally, Asymmetry Capital Management L.P. bought a new stake in Intercept Pharmaceuticals in the 2nd quarter valued at about $3,580,000. Institutional investors and hedge funds own 73.79% of the company’s stock.

In other news, CEO Mark Pruzanski sold 1,532 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,566 shares of company stock valued at $151,025 in the last three months. 9.20% of the stock is owned by insiders.

Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at $61.21 on Monday. Intercept Pharmaceuticals, Inc. has a twelve month low of $54.98 and a twelve month high of $135.59. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million during the quarter, compared to analyst estimates of $36.95 million. During the same quarter in the previous year, the firm earned ($3.59) earnings per share. Intercept Pharmaceuticals’s revenue was up 697.9% on a year-over-year basis. research analysts anticipate that Intercept Pharmaceuticals, Inc. will post -13.35 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on the company. ValuEngine upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Wedbush reiterated an “outperform” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 25th. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Cantor Fitzgerald reiterated an “underweight” rating and set a $69.00 price target (up from $60.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 8th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $221.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Intercept Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $144.13.

COPYRIGHT VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/04/stonepine-capital-management-llc-takes-position-in-intercept-pharmaceuticals-inc-icpt.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.